Exploratory study to assess the Efficacy of the Homoeopathic Medicines Medorrhinum 1m,Stelleria Media Q and Chininum Sulph 6c in combination in the treatment of Rheumatoid Arthritis patients,
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Reduction in ESR,CRP,Anti CCP antibodies and Rheumatoid factor.
研究概览
简要总结
Rheumatoid arthritis is the most common inflammatory arthritis and autoimmune disease that us associated with progressive disability,systemic complications,early death and socioeconomic costs.RA occurs in 0.5-1.0% of the adult population worldwide and is more common in women.In Indian prevalence is ranging between 0.19-2.50%.The peak incidence is between the ages of 20 and 40,the most productive years of adulthood.
Patients often complain of pain & early morning joint stiffness lasting> 1 hour.Typically the small joints of hands and feet are affected with a poly articular (>5 joints) symmetric distribution.Later it may affect the large joints.The classical Extra-articular manifestations of RA are also extensive.
The confirmatory diagnosis may be done with ’2010 American College of Rheumatology/ European League against Rheumatism Classification Criteria for RA’.
RA has a significant negative impact on the ability to perform daily activities,including work & household tasks, and health related quality of life, The goal of treatment in RA patients is to eliminate symptoms,slow disease progression and optimize quality of life.
Since the Medicine combination of Medorrhinum 1m,Stelleria Media Q and Chininum Sulph 6c has not yet been clinically tested for its effectiveness in the treatment of Rheumatoid Arthritis,the proposed Research project will be a pioneer Clinical Research outcome if preceded.
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 盲法
- Not Applicable
入排标准
- 年龄范围
- 25.00 Year(s) 至 75.00 Year(s)(—)
- 性别
- All
入选标准
- •Patients fulfilling the 2010 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Rheumatoid arthritis.
排除标准
- •Patients with systemic Complications and deformities.
- •patients with Extra-articular manifestations.
- •Patients under Chronic medication for Rheumatoid Arthritis.
结局指标
主要结局
Reduction in ESR,CRP,Anti CCP antibodies and Rheumatoid factor.
时间窗: 180 days
reduction in Rheumatoid Arthritis Impact of Disease (RAID)Scores and Visual Analogue Pain Scale.
时间窗: 180 days
次要结局
- Improvement in Quality of life(180 days)
